ArticleJournal of extracellular vesicles2026
M2 Macrophage-Derived Small Extracellular Vesicle miR-106a-Loaded QCG Hydrogel Targets the RNF128-LXR Pathway to Reprogram Chondrocyte Cholesterol Metabolism for Osteoarthritis Therapy.
Article in Journal of extracellular vesicles, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- M2 Macrophage-Derived Small Extracellular Vesicle miR-106a-Loaded QCG Hydrogel Targets the RNF128-LXR Pathway to Reprogram Chondrocyte Cholesterol Metabolism for Osteoarthritis Therapy.Journal of extracellular vesicles · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study addresses osteoarthritis (OA), in which dysregulated chondrocyte cholesterol homeostasis and cellular senescence contribute to cartilage degeneration, by developing an inflammation-responsive injectable QCG hydrogel for local delivery of miR-106a-enriched M2 macrophage-derived small extracellular vesicles (sEVs). The QCG hydrogel was constructed from quaternized chitosan (QCS) and 4-carboxyphenylboronic acid-gelatin (CPBA-gelatin) and loaded with miR-106a-enriched M2-sEVs (QCG@sEV-miR-106a). M2-sEVs were isolated by differential ultracentrifugation and characterized by transmission electron microscopy, nanoparticle tracking analysis, and vesicle-associated protein markers. High-throughput miRNA profiling and chondrocyte RNA sequencing identified miR-106a as a candidate regulatory molecule, and RNF128 was confirmed as a direct target by dual-luciferase reporter assay. Functional experiments showed that miR-106a suppresses RNF128, thereby promoting chondrocyte proliferation and extracellular matrix synthesis while attenuating senescence. Exploratory proteomic screening suggested RNF128-associated changes in cholesterol- and lysosome-related processes, whereas independent molecular and functional assays demonstrated that RNF128 promotes LXRα ubiquitination and proteasome-dependent degradation, suppresses LXR signaling, and disrupts cholesterol homeostasis. In a destabilization of the medial meniscus (DMM)-induced OA rat model, QCG@sEV-miR-106a showed ROS-responsive release, prolonged intra-articular retention for up to 22 days, reduced cartilage degeneration and matrix loss, improved pain-related behaviors, and favorable short-term biocompatibility. Together, these findings support a local biomaterial delivery strategy in which miR-106a-mediated RNF128 inhibition preserves LXR signaling and cholesterol homeostasis to attenuate OA-associated chondrocyte senescence.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.